Unrelated DonorsTissue DonorsHistocompatibility TestingGraft vs Host DiseaseHistocompatibilityTransplantation, HomologousBone Marrow TransplantationTransplantation ConditioningHematopoietic Stem Cell TransplantationHematologic NeoplasmsLiving DonorsBlood DonorsCord Blood Stem Cell TransplantationHLA AntigensGraft SurvivalLeukemiaAnemia, AplasticRecurrenceTreatment OutcomeAntilymphocyte SerumPeripheral Blood Stem Cell TransplantationDonor SelectionVidarabineSurvival AnalysisMyeloablative AgonistsSiblingsWhole-Body IrradiationDisease-Free SurvivalPrecursor Cell Lymphoblastic Leukemia-LymphomaHLA-DP beta-ChainsTransplantation ChimeraImmunosuppressive AgentsBusulfanRetrospective StudiesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHematologic DiseasesSurvival RateFetal BloodLymphocyte DepletionMyelodysplastic SyndromesAcute DiseaseGraft RejectionHLA-DP AntigensHemibody IrradiationLeukemia, Myeloid, AcuteTransplantation ImmunologyTissue and Organ ProcurementAllograftsHLA-A AntigensDirected Tissue DonationLife TablesRemission InductionCyclosporineStem Cell TransplantationActuarial AnalysisHistiocytosis, Non-Langerhans-CellHLA-B AntigensHLA-C AntigensMethotrexateTacrolimusInfectionRegistriesTransplantsTime FactorsFollow-Up StudiesKidney TransplantationWiskott-Aldrich SyndromeCause of DeathSevere Combined ImmunodeficiencyHLA-DRB1 ChainsMetabolism, Inborn ErrorsTransplantation, AutologousAllelesGraft vs Leukemia EffectT-LymphocytesRisk FactorsFanconi AnemiaCytomegalovirus InfectionsGraft vs Tumor EffectMelphalanLymphocyte TransfusionMycophenolic AcidCyclophosphamideIncidenceImmunosuppressionLeukemia, Myelomonocytic, AcuteHLA-DR AntigensAntibodies, NeoplasmHaplotypesAnemia, Refractory, with Excess of BlastsCadaverChronic DiseaseMethylprednisoloneChimerismTransplantation, IsogeneicInfant, NewbornGenetic Diseases, InbornPrognosisReceptors, KIRLeukemia, Myeloid